The company’s signature Compounding System Solution integrates proprietary software with GMP-manufactured excipient bases to automate the creation of tailored drug dosages. By replacing manual pharmacy preparation with high-speed 3D printing, CurifyLabs aims to improve both the precision and safety of patient-specific therapies. Their latest hardware iteration, the PharmaPrinter Aurum, reportedly compounds medications up to nine times faster than traditional methods, meeting ISO 13485 certification and FDA 503A/503B standards for non-sterile compounding.

Currently, the firm’s technology is deployed in 21 U.S. states and across Europe, where it processes thousands of daily doses. CEO and founder Charlotta Topelius stated that the fresh capital will be directed toward strengthening supply chain infrastructure and enhancing product innovation. Investors see the move as a validation of Finnish health technology’s ability to scale globally, with HealthCap’s Daniel Karsberg noting the team’s rare ability to bridge the gap between deep clinical rigor and rapid real-world execution.